Cargando…

Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)

Medical therapy for hereditary hepatorenal tyrosinemia (hereditary tyrosinemia type 1, HT-1) with nitisinone was discovered incidentally, and is a by-product of agrochemistry. It blocks the catabolic pathway of tyrosine, thereby leading to a reduction in the accumulation of toxic metabolites in HT-1...

Descripción completa

Detalles Bibliográficos
Autor principal:	Das, Anibh Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533484/ https://www.ncbi.nlm.nih.gov/pubmed/28769581 http://dx.doi.org/10.2147/TACG.S113310

Ejemplares similares

Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain
por: Couce, María Luz, et al.
Publicado: (2019)

Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype
por: Neuckermans, Jessie, et al.
Publicado: (2023)

Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia
por: HONAR, Naser, et al.
Publicado: (2017)

Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review
por: Geppert, Julia, et al.
Publicado: (2017)

Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation
por: Colemonts-Vroninks, Haaike, et al.
Publicado: (2020)

Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet
por: García, María Ignacia, et al.
Publicado: (2017)

Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 1
por: Guffon, Nathalie, et al.
Publicado: (2017)

Validation of a therapeutic range for nitisinone in patients treated for tyrosinemia type 1 based on reduction of succinylacetone excretion
por: Jack, Rhona M., et al.
Publicado: (2019)

Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria
por: Hughes, Juliette H., et al.
Publicado: (2020)

Short-term nitisinone discontinuation of hereditary tyrosinemia type 1 mice causes metabolic alterations in glutathione metabolism/biosynthesis and multiple amino acid degradation pathways
por: Haaike, Colemonts-Vroninks, et al.
Publicado: (2022)

Revisiting hereditary tyrosinemia Type 1—spectrum of radiological findings
por: Shaikh, Sana, et al.
Publicado: (2018)

Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study
por: Megdadi, Noor A., et al.
Publicado: (2021)

Syndrome of hereditary tyrosinemia in mink
por: Christensen, K, et al.
Publicado: (1978)

Protein Degradation and the Pathologic Basis of Phenylketonuria and Hereditary Tyrosinemia
por: Sarodaya, Neha, et al.
Publicado: (2020)

Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1
por: Li, Li, et al.
Publicado: (2017)

Phenotype, genotype, and outcome of 25 Palestinian patients with hereditary tyrosinemia type 1
por: Dweikat, Imad, et al.
Publicado: (2021)

Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver
por: Ren, Jilong, et al.
Publicado: (2022)

Treatment adherence in tyrosinemia type 1 patients
por: González-Lamuño, Domingo, et al.
Publicado: (2021)

Therapeutic Targeting of Fumaryl Acetoacetate Hydrolase in Hereditary Tyrosinemia Type I
por: Gil-Martínez, Jon, et al.
Publicado: (2021)

Comment on Pancreatitis in Type 1 Tyrosinemia
por: Rahmoune, Hakim, et al.
Publicado: (2017)

The compound heterozygous mutations of c.607G>a and c.657delC in the FAH gene are associated with renal damage with hereditary tyrosinemia type 1 (HT1)
por: Chi, Huan, et al.
Publicado: (2022)

Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts
Publicado: (1985)

Diagnostic and Therapeutic Challenges of Hereditary Tyrosinemia Type 1 in Lebanon: A 12-Year Retrospective Review
por: Daou, Karim N., et al.
Publicado: (2021)

Hepatorenal tyrosinemia
por: KITAGAWA, Teruo
Publicado: (2012)

The Discovery of the Mode of Action of Nitisinone
por: Lock, Edward A.
Publicado: (2022)

Type 1 tyrosinemia in Finland: a nationwide study
por: Äärelä, Linnea, et al.
Publicado: (2020)

Case report: ADHD and prognosis in tyrosinemia type 1
por: Barone, Helene, et al.
Publicado: (2023)

Identification of circulating microRNAs during the liver neoplastic process in a murine model of hereditary tyrosinemia type 1
por: Angileri, Francesca, et al.
Publicado: (2016)

The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism
por: Thompson, Whitney S., et al.
Publicado: (2020)

In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions
por: Nicolas, Clara T., et al.
Publicado: (2022)

Heat Shock Response Associated with Hepatocarcinogenesis in a Murine Model of Hereditary Tyrosinemia Type I
por: Angileri, Francesca, et al.
Publicado: (2014)

Experience of a Single Center in NTBC Use in Management of Hereditary Tyrosinemia Type I in Libya
por: Alobaidy, Hanna, et al.
Publicado: (2015)

Initial presentation, management and follow-up data of 33 treated patients with hereditary tyrosinemia type 1 in the absence of newborn screening
por: Hajji, Hela, et al.
Publicado: (2022)

Hereditary Tyrosinemia Compounded With Hyperinsulinemic Hypoglycemia: Challenging Diagnosis of a Rare Case
por: Nasir, Sharmeen, et al.
Publicado: (2020)

Severe neurological crisis in adult patients with Tyrosinemia type 1
por: Dawson, Charlotte, et al.
Publicado: (2020)

Preventive use of nitisinone in alkaptonuria
por: Wolffenbuttel, Bruce H. R., et al.
Publicado: (2021)

Adequacy of nitisinone for the management of alkaptonuria
por: Abbas, Khawar, et al.
Publicado: (2022)

Tyrosinemia type III in an asymptomatic girl
por: Szymanska, Edyta, et al.
Publicado: (2015)

Exploring the therapeutic potential of modern and ancestral phenylalanine/tyrosine ammonia-lyases as supplementary treatment of hereditary tyrosinemia
por: Hendrikse, Natalie M., et al.
Publicado: (2020)

Case of hepatocellular carcinoma in a patient with hereditary tyrosinemia in the post-newborn screening era
por: Imseis, Essam M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lmkthv3gbtbvd6mj6glaftj1k1